FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2490617194> ?p ?o ?g. }

• W2490617194 endingPage "651" @default.
• W2490617194 startingPage "641" @default.
• W2490617194 abstract "Dinaciclib is a cyclin-dependent kinase inhibitor with clinical potential in different cancers, including chronic lymphocytic leukaemia (CLL). In order to better understand its cytotoxic action, we characterized its effects on signalling pathways important for the survival of CLL cells. We found that dinaciclib induced apoptosis through the activation of caspases 8 and 9, which was independent of the presence of cytokines to mimic the environment of proliferation centres or IGVH mutation status. Moreover, treatment with dinaciclib led to the inhibition of oncogenic pathways normally activated in stimulated CLL cells, such as STAT3, NF-κB, p38, PI3K/AKT and RAF/MEK/ERK. Dinaciclib was also able to block the expression of anti-apoptotic proteins of the BCL2 family such as MCL1 and BCL-xL (also termed BCL2L1). Finally, we showed that low concentrations of dinaciclib enhanced cell sensitivity to ibrutinib and the BCL2 inhibitor ABT-199, two drugs with known effects on CLL. Taken together, our data show that dinaciclib targets multiple pro-survival signalling pathways in CLL, which provides a mechanistic explanation for its potent induction of apoptosis. They also support a therapeutic application of cyclin-dependent kinase inhibitors in CLL in combination with other relevant targeted therapies." @default.
• W2490617194 created "2016-08-23" @default.
• W2490617194 creator A5004727576 @default.
• W2490617194 creator A5012542183 @default.
• W2490617194 creator A5031754489 @default.
• W2490617194 creator A5054605332 @default.
• W2490617194 creator A5058272535 @default.
• W2490617194 creator A5081516283 @default.
• W2490617194 creator A5087953918 @default.
• W2490617194 creator A5088901076 @default.
• W2490617194 date "2016-07-29" @default.
• W2490617194 modified "2023-10-17" @default.
• W2490617194 title "Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia" @default.
• W2490617194 cites W1499230593 @default.
• W2490617194 cites W1535142282 @default.
• W2490617194 cites W180295822 @default.
• W2490617194 cites W1840112861 @default.
• W2490617194 cites W1965570423 @default.
• W2490617194 cites W1972564258 @default.
• W2490617194 cites W1982494540 @default.
• W2490617194 cites W1983579522 @default.
• W2490617194 cites W1989929255 @default.
• W2490617194 cites W1993192840 @default.
• W2490617194 cites W1993986769 @default.
• W2490617194 cites W1994740077 @default.
• W2490617194 cites W1999753979 @default.
• W2490617194 cites W2011192988 @default.
• W2490617194 cites W2012957572 @default.
• W2490617194 cites W2027901215 @default.
• W2490617194 cites W2038258256 @default.
• W2490617194 cites W2046024621 @default.
• W2490617194 cites W2050818262 @default.
• W2490617194 cites W2055576683 @default.
• W2490617194 cites W2055969647 @default.
• W2490617194 cites W2056423963 @default.
• W2490617194 cites W2060508679 @default.
• W2490617194 cites W2063644591 @default.
• W2490617194 cites W2065117608 @default.
• W2490617194 cites W2067064694 @default.
• W2490617194 cites W2068720118 @default.
• W2490617194 cites W2071549499 @default.
• W2490617194 cites W2075875145 @default.
• W2490617194 cites W2077165680 @default.
• W2490617194 cites W2078493126 @default.
• W2490617194 cites W2081107312 @default.
• W2490617194 cites W2085648789 @default.
• W2490617194 cites W2087647272 @default.
• W2490617194 cites W2092975278 @default.
• W2490617194 cites W2100246815 @default.
• W2490617194 cites W2102461774 @default.
• W2490617194 cites W2103580937 @default.
• W2490617194 cites W2104773756 @default.
• W2490617194 cites W2106293966 @default.
• W2490617194 cites W2120535935 @default.
• W2490617194 cites W2121396722 @default.
• W2490617194 cites W2127929077 @default.
• W2490617194 cites W2129633905 @default.
• W2490617194 cites W2129679336 @default.
• W2490617194 cites W2131017274 @default.
• W2490617194 cites W2131826846 @default.
• W2490617194 cites W2135699328 @default.
• W2490617194 cites W2139771411 @default.
• W2490617194 cites W2140642045 @default.
• W2490617194 cites W2142099365 @default.
• W2490617194 cites W2154119344 @default.
• W2490617194 cites W2157023753 @default.
• W2490617194 cites W2167690894 @default.
• W2490617194 cites W2172242534 @default.
• W2490617194 cites W2175111412 @default.
• W2490617194 cites W2194216566 @default.
• W2490617194 cites W2274760439 @default.
• W2490617194 cites W2333776332 @default.
• W2490617194 cites W2341932560 @default.
• W2490617194 cites W4253103866 @default.
• W2490617194 cites W957112403 @default.
• W2490617194 doi "https://doi.org/10.1111/bjh.14285" @default.
• W2490617194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27469405" @default.
• W2490617194 hasPublicationYear "2016" @default.
• W2490617194 type Work @default.
• W2490617194 sameAs 2490617194 @default.
• W2490617194 citedByCount "24" @default.
• W2490617194 countsByYear W24906171942017 @default.
• W2490617194 countsByYear W24906171942018 @default.
• W2490617194 countsByYear W24906171942019 @default.
• W2490617194 countsByYear W24906171942020 @default.
• W2490617194 countsByYear W24906171942021 @default.
• W2490617194 countsByYear W24906171942022 @default.
• W2490617194 countsByYear W24906171942023 @default.
• W2490617194 crossrefType "journal-article" @default.
• W2490617194 hasAuthorship W2490617194A5004727576 @default.
• W2490617194 hasAuthorship W2490617194A5012542183 @default.
• W2490617194 hasAuthorship W2490617194A5031754489 @default.
• W2490617194 hasAuthorship W2490617194A5054605332 @default.
• W2490617194 hasAuthorship W2490617194A5058272535 @default.
• W2490617194 hasAuthorship W2490617194A5081516283 @default.
• W2490617194 hasAuthorship W2490617194A5087953918 @default.
• W2490617194 hasAuthorship W2490617194A5088901076 @default.
• W2490617194 hasBestOaLocation W24906171941 @default.

• next